曼氏血吸虫疫苗联合或单用GLA-AF佐剂的I期安全性、反应原性与免疫原性研究
疫苗安全耐受,GLA-AF组注射部位疼痛和压痛更常见,联合GLA-AF的30μg和100μg剂量组血清阳转率显著高于安慰剂,且呈剂量反应关系。
要点
- Sm-TSP-2/Al疫苗联合或不联合GLA-AF在曼氏血吸虫未暴露成人中安全且耐受良好。
- 联合GLA-AF组注射部位压痛和疼痛较安慰剂更常见,局部反应持续时间延长约1.2-1.3天。
- 联合GLA-AF的30μg和100μg剂量组血清阳转率分别为50%和89%,显著高于安慰剂,呈剂量反应关系。
核心结论
- Sm-TSP-2/Al疫苗联合或不联合GLA-AF在曼氏血吸虫未暴露人群中安全且耐受良好。
- 联合GLA-AF的30μg和100μg剂量组血清阳转率显著高于安慰剂,且呈剂量反应关系。
研究设计与样本
- 第3剂后随访1年评估临床和血清学反应。
主要发现
- 疫苗安全且耐受良好,最常见反应为注射部位压痛和疼痛、头痛和疲劳。
- 联合GLA-AF组压痛和疼痛较安慰剂更频繁(p=0.0036和p=0.0014)。
- 联合GLA-AF组注射部位反应持续时间较单用Sm-TSP-2/Al或安慰剂组分别延长1.22天和1.33天(均p<0.001)。
- 观察到针对Sm-TSP-2的血清IgG剂量和佐剂相关增加,峰值出现在第3剂后14天。
- 联合GLA-AF的30μg和100μg组血清阳转率较安慰剂更高(p=0.023和p<0.001),血清阳转率分别为0%、30%、50%和89%(安慰剂、10μg、30μg、100μg联合GLA-AF组),呈剂量反应关系(p=0.0001)。
关键数值与推荐
- 联合GLA-AF的30μg和100μg组血清阳转率分别为50%和89%,显著高于安慰剂(0%)(p=0.023和p<0.001)。
- 联合GLA-AF组血清阳转率呈剂量反应关系(p=0.0001)。
- 联合GLA-AF组注射部位压痛和疼痛较安慰剂更频繁(p=0.0036和p=0.0014)。
- 联合GLA-AF组注射部位反应持续时间较单用Sm-TSP-2/Al或安慰剂组分别延长1.22天和1.33天(均p<0.001)。
临床怎么用
- 该I期试验支持Sm-TSP-2/Al疫苗联合GLA-AF在曼氏血吸虫未暴露成人中进一步开展临床开发。
- 联合GLA-AF可增强血清抗体应答,但需关注注射部位反应频率和持续时间的增加。
局限性
- 本研究为I期试验,样本量有限,仅纳入曼氏血吸虫未暴露健康成人,结果不能外推至流行区人群。
- 未评估疫苗对血吸虫感染的保护效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Schistosomiasis caused by Schistosoma mansoni (Sm) is a chronic, debilitating and potentially deadly neglected tropical disease. The licensure of a vaccine to prevent schistosomiasis would represent a major breakthrough in public health. METHODS: The safety and immunogenicity of a candidate Sm vaccine were assessed in this phase I, double-blind, dose-escalation trial. Seventy-two healthy Sm-naïve 18-50 year olds were randomized to receive 3 doses ∼ 8 weeks apart of saline placebo, or 10 µg, 30 µg, or 100 µg of recombinant Sm-Tetraspanin-2 vaccine formulated on aluminum hydroxide adjuvant (Sm-TSP-2/Al) with or without 5 µg of glucopyranosyl lipid A aqueous formulation (GLA-AF). Clinical and serologic responses were assessed for 1 year after dose 3. RESULTS: Vaccines were safe and well-tolerated. The most common reactions were injection site tenderness and pain, and headache and fatigue. Tenderness and pain were more frequent in groups receiving vaccine with GLA-AF than placebo (p = 0.0036 and p = 0.0014, respectively). Injection site reactions among those given Sm-TSP-2/Al with GLA-AF lasted 1.22 and 1.33 days longer than those receiving Sm-TSP-2/Al without GLA-AF or placebo (p < 0.001 for both). Dose- and adjuvant-related increases in serum IgG against Sm-TSP-2 were observed. Peak IgG levels occurred 14 days after dose 3. Seroresponse frequencies were low among recipients of Sm-TSP-2/Al without GLA-AF, but higher among subjects receiving 30 µg or 100 µg of Sm-TSP-2/Al with GLA-AF. More seroresponses were observed among those given 30 µg or 100 µg of Sm-TSP-2/Al with GLA-AF compared to placebo (p = 0.023 and p < 0.001, respectively). Seroresponse frequencies were 0%, 30%, 50%, and 89%, respectively, among those given placebo, or 10 µg, 30 µg or 100 µg of Sm-TSP-2/Al with GLA-AF, suggesting a dose-response relationship for Sm-TSP-2/Al with GLA-AF (p = 0.0001). CONCLUSIONS: Sm-TSP-2/Al with or without GLA-AF was safe and well tolerated in a Sm-naïve population. A vaccine like the one under development may represent our best hope to eliminating this neglected tropical disease.
引用
- Keitel WA, Potter GE, Diemert D, et al. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019. PMID: 31515141. doi:10.1016/j.vaccine.2019.08.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。